AlphAIAlphAI — Financial news for AI agents
finanznachrichten.deSEP 32 min read$PDEX

Pro-Dex, Inc. Announces Fiscal 2026 Fourth Quarter and Full-Year Results

Pro-Dex (PDEX) reported Q4 2026 net sales of $20.4M, up 17% YoY, and net income of $2.9M ($0.87 per share). Full-year 2026 sales rose 16% to $77.5M, with net income at $13.7M ($4.12 per share). Growth was driven by increased revenue from a major customer's next-gen handpiece and the acquisition of APM.

Original reporting
finanznachrichten.de
Published Sep 3, 2026, 9:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 3, 2026, 9:29 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$PDEX
Bullish
high confidence
Mentioned
$PDEX
Relevance
7/10
AlphAI data visualization · based on finanznachrichten.de
Decision brief

The 30-second read

$PDEXBullishHigh
01

Why it matters

The earnings beat and margin expansion are likely to drive short‑term price appreciation, though cost increases warrant caution.

02

Market read

First‑report earnings release for a small‑cap med‑tech firm with notable revenue growth and margin improvement.

03

What to watch

Higher operating expenses and one‑off consulting fees could pressure future margins.

Relevance 7/10Novelty 8/10Timing: post‑release September 3 2026

Background

Pro‑Dex, a developer of surgical drivers and shavers, released its FY2026 earnings after acquiring Advanced Precision Machining.

Company-level read

Ticker impact

$PDEXBullishHigh confidence
Context

Pro-Dex reported Q4 and full-year FY2026 results with 16% revenue growth and higher net income.

Expected impact

Potential upside as investors price in higher earnings and margin expansion.

Evidence & confidence

Revenue and profit beat, margin expansion, and acquisition synergies suggest better future cash flow.

Market effects

Sector

Positive signal for orthopedic device and medical‑device manufacturing sector.

Regional

Boosts sentiment for US small‑cap biotech/med‑tech stocks.

Global

Limited to niche medical‑device market, no broad macro effect.

Counterpoint

What could challenge this read

Investors may question sustainability of growth given reliance on a single large customer.

Key entities

  • Company
    Pro‑Dex, Inc.

    Medical‑device manufacturer reporting FY2026 results.

  • Subsidiary
    Advanced Precision Machining, LLC

    Acquired in Q3 2026, contributes to revenue and margin.

Read at source← All news

Also covered by

1 outlet

Related articles

SEP 3
$PDEXMed

PRO DEX INC (PDEX): Quarter Ended June 30, 2026

PRO DEX INC (PDEX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Contact: Richard L. Van Kirk, Chief Executive Officer (949) 769-3200 For Immediate Release PRO-DEX, INC. ANNOUNCES FISCAL 2026 FOURTH QUARTER AND FULL-YEAR RESULTS IRVINE, CA, September 3, 2026 - PRO-DEX, INC. (NasdaqCM: PDEX) t oday announced financial results for i

SEC EDGAR 8-K2 min
OCT 25
$GOOGLMedAI 8/10

Big Tech Earnings Put AI Returns in Focus Ahead of Fed Decision

Alphabet, Microsoft, and Amazon will report earnings this week, with investors focusing on AI spending returns. The Nasdaq fell 0.21% Friday, and 32% YoY earnings growth is seen in S&P 500 companies. The Fed meets Oct. 27-28, with a 25bps rate hike in September. Meta reported $64.6B Q3 revenue, up 26% YoY, and raised its 2026 cap-ex outlook to $135B-$145B.

econotimes.com2 min
OCT 25
$SPCXMedAI 8/10

SpaceX Could Weather a Recession. But Its Stock Might Not. Here's Why.

SpaceX (SPCX) reported Q3 revenue of $14.6B (+161% YoY) and net income of $4.4B. Starlink, its satellite broadband service, saw 69% YoY revenue growth to $5.2B and 13.6M subscribers. However, average revenue per subscriber fell to $69. The company is investing heavily in AI and other projects, spending $19.6B in Q3. Despite strong business prospects, its high valuation (PS ratio of 64) may make shares vulnerable to market sentiment shifts.

finance.yahoo.com3 min